301163-47-3

Upstream product

• 1189164-12-2 2-bromo-5,6-dimethyl-1H-benzo[d]imidazole 
• 156-87-6 propan-1-ol-3-amine 
• 3287-79-4 5,6-dimethyl-2-mercaptobenzimidazole 
• 3171-45-7 4,5-dimethyl-1,2-phenylenediamine 

Downstream Products

• 758679-97-9 AJW-200 
• 1224437-04-0 C₂₈H₃₇N₃O₂ 
• 1189164-11-1 1-(3,5-di-tert-butyl-4-methoxyphenyl)-2-(2-(3-hydroxypropylamino)-5,6-dimethyl-1H-benzo[d]imidazol-1-yl)ethanone 
• 1189164-52-0 C₂₀H₂₃N₃O₃ 
• 1189164-50-8 C₂₂H₂₇N₃O₃ 
• 1135317-74-6 1-(3,5-di-tert-butylphenyl)-2-(2-(3-hydroxypropylamino)-5,6-dimethyl-1H-benzo[d]imidazol-1-yl)ethanone 
• 1222877-91-9 1-(3-tert-butylphenyl)-2-(2-(3-hydroxypropylamino)-5,6-dimethyl-1H-benzo[d]imidazol-1-yl)ethanone 
• 1224628-08-3 1-(3-tert-butoxyphenyl)-2-(2-(3-hydroxypropylamino)-5,6-dimethyl-1H-benzo[d]imidazol-1-yl)ethanone 

Relevant academic research and scientific papers

Synthesis and physicochemical characterization of novel phenotypic probes targeting the nuclear factor-kappa B signaling pathway

Activation of nuclear factor-kappa B (NF-κB) and related upstream signal transduction pathways have long been associated with the pathogenesis of a variety of inflammatory diseases and has recently been implicated in the onset of cancer. This report provi

Inhibition of protein kinase C-driven nuclear factor-κB activation: Synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules

A unique series of biologically active chemical probes that selectively inhibit NF-κB activation induced by protein kinase C (PKC) pathway activators have been identified through a cell-based phenotypic reporter gene assay. These 2-aminobenzimidazoles represent initial chemical tools to be used in gaining further understanding on the cellular mechanisms driven by B and T cell antigen receptors. Starting from the founding member of this chemical series 1a (notated in PubChem as CID-2858522), we report the chemical synthesis, SAR studies, and pharmacological profiling of this pathway-selective inhibitor of NF-κB activation.

Selective benzimidazole inhibitors of the antigen receptor-mediated NF-κB activation pathway

Dysregulated antigen receptor-mediated NF-κB activation can contribute to development of autoimmunity, chronic inflammation, and malignancy. A chemical biology screening strategy has identified a substituted benzimidazole that selectively inhibits antigen receptor-mediated NF-κB activation without blocking other NF-κB activation pathways. A library of analogs was synthesized and the structure-activity relationship and metabolic stability for the series is presented.

INHIBITORS OF ANTIGEN RECEPTOR-INDUCED NF-kappa B ACTIVATION

A method to identify selective inhibitors of antigen receptor-mediated NF-κB activation is provided, as well as compositions having one or more of those inhibitors and methods of using those inhibitors.